 |
 | Increased Survival And Improved Quality Of Life For End-Sta |  |
|
RSS FEED
|
|
A gene therapy invented at The University of Texas M. D. Anderson Cancer Center is the first to succeed in a U.S. phase III clinical trial for cancer, as announced at the American Society of Gene Therapy annual meeting in Boston.Introgen Therapeutics, Inc., reported results of its phase III trial of Advexin(r), a modified adenovirus that expresses the tumor-suppressing gene p53, for end-stage head and neck cancer.
Read more... |
|||||||||||
|
|||||||||||||
 |
 | Increased Survival And Improved Quality Of Life For End-Sta | |
|
||
|
|
|
Site Map
|
Sitemap |